Biogen's Scangos sees potential to dominate hemophilia market
This article was originally published in Scrip
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Eli Lilly said its unapproved long-acting treatment dulaglutide worked as well as Novo Nordisk’s big-selling therapy Victoza controlling diabetics’ blood-sugar levels in a study.